We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry.
Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.
Our platform enables frequent, remote multi-domain sampling outside of the clinic to dramatically improve the robustness of neuroscience clinical trials. These assessments enable more robust and timely decision making in therapeutic development programmes. Our domain assessment technologies have been carefully designed for low patient burden and repeated use, and extensively field-tested by hundreds of users over thousands of hours in patient and control populations.
We assess cognition with patients in their home setting using tablet-based, real-world translations of lab-based tasks. These have been designed for repeated longitudinal assessment of working memory, episodic memory, executive function, decision making, and other cognitive functions. We continually look to include more tests as they become relevant and compatible with home use.
We have developed a first-in-class home usable EEG headset that can track neuronal integrity, network connectivity and compensation strategies, synchronised with tablet-based functional assessments of behavioural domains. All in a secure cloud-based storage and machine learning architecture that allows us to safely analyse composite behavioural, physiological and functional data
Our platform integrates P1vital Products’ Facial Expression Recognition Task (FERT) to assess emotional bias. P1vital is a leader in computerised behavioural testing in clinical trials for mood and other psychiatric domains. The P1vital FERT is a well validated objective assessment of how someone processes emotional information and can provide an indication of current mood. The FERT is used widely in both clinical trials and healthcare settings to provide an early detection of treatment response.
Our platform integrates Winterlight Labs’ state of the art algorithms and database to assess word choice, grammar and the acoustic properties of speech. Winterlight Labs has developed a proprietary language-based diagnostic system that analyses natural speech to detect and monitor dementias including Alzheimer’s, aphasia, and various other cognitive conditions.
Our platform integrates easy-to-use, clinically-validated sleep assessment tools that enable remote measurement of sleep quality metrics and sleep staging.
Powerful proprietary machine learning-based methods allow us to automatically evaluate the rich multi-dimensional real-world data we collect and rapidly generate meaningful insights. This allows detection of small but highly relevant changes in patients and provides the best and most cost-effective assessment of treatment outcomes, to maximize the chances of trial success.
Former CEO PathXL, pioneering digital pathology company acquired by Philips Healthcare in 2016. Board member of lifesciences / deep tech companies and QUB Ventures.
Venture partner SV Health Investors, co-founder of DDF companies Loqus23 and AstronauTX. 25 years’ experience in Pharma at Merck and Pfizer. Trustee Alzheimer’s Research UK, Chair of UK’s BioIndustry Association.
Investment Principal, LifeArc Seed Fund. Ph.D. in Cell Signalling from Imperial College London. 20+ years experience in early-stage life sciences investment, business development, and IP protection, licensing, and exploitation.
Venture Partner at SV, Former CEO of Cenduit, Head of Connected devices at Quintiles. Strong track record in product launches, growth businesses. Multiple new technology product launches leading to >$50M growth in under 36 months.
Founder, CEO and Chairman or Board Member of biopharma and technology companies, Chairman or Trustee of major industry bodies including UK BIA.
Prof. Ritchie is Professor of the Psychiatry of Ageing at the University of Edinburgh and Director of Brain Health Scotland. He is a leading authority on clinical trials in Alzheimer’s disease and leads two major cohort studies: the European Prevention of Alzheimer’s Dementia (EPAD) and PREVENT Dementia Programmes.
Dr. Hughes is former Vice President and Head of CNS Growth Strategy at IQVIA. She is an expert in neurocognitive assessment and design of appropriate studies to assess Alzheimer’s Disease and neurocognitive dysfunction.
Prof. Jaeger is President of CognitionMetrics, LLC and Prof. Clinical Psychiatry & Behavioural Sciences at Albert Einstein College of Medicine. Former positions include Vice President for Clinical Trials at Cogstate and Director Clinical Development at AstraZeneca Pharmaceuticals.
Prof. McDade specialises in cognitive and behavioural neurology. He is Associate Professor of Neurology at Washington University School of Medicine in St Louis. and Associate Director of the DIAN Trials Unit.
Gerry Reilly is Technologist in Residence at Health Data Research UK, the national institute for health data in the UK, where he is senior advisor on long-term trends in technology and computer science, imaging and privacy enhancing technologies. He is also a member of the Executive Leadership Team for the International COVID-19 Data Alliance.
Mr. Mather is an Executive Director in Pfizer’s Early Clinical Development organization and has more than 20 years of experience in pharmaceutical research. He leads Pfizer’s Advanced Science group, validating technology platforms and qualifying novel digital endpoints.
At Cumulus, we work closely with leading pharmaceutical and biotech companies to deliver innovative digital solutions that improve and accelerate the development of transformational therapies for CNS disorders. Our integrated biomarker platform is being co-developed with six of the world’s leading pharmaceutical companies.
Cumulus is backed by experienced life science and technology investors, as well as UK and EU backed innovation agencies.